383 related articles for article (PubMed ID: 30446657)
21. YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma.
Yang C; Tan J; Zhu J; Wang S; Wei G
Oncotarget; 2017 Jun; 8(23):37154-37163. PubMed ID: 28415761
[TBL] [Abstract][Full Text] [Related]
22. Knockdown of yes-associated protein inhibits proliferation and downregulates large tumor suppressor 1 expression in MHCC97H human hepatocellular carcinoma cells.
Wang C; Zhu ZM; Liu CL; He XJ; Zhang HY; Dong JH
Mol Med Rep; 2015 Jun; 11(6):4101-8. PubMed ID: 25625370
[TBL] [Abstract][Full Text] [Related]
23. CIZ1 interacts with YAP and activates its transcriptional activity in hepatocellular carcinoma cells.
Lei L; Wu J; Gu D; Liu H; Wang S
Tumour Biol; 2016 Aug; 37(8):11073-9. PubMed ID: 26906552
[TBL] [Abstract][Full Text] [Related]
24. TNFAIP8 interacts with LATS1 and promotes aggressiveness through regulation of Hippo pathway in hepatocellular carcinoma.
Dong Q; Fu L; Zhao Y; Xie C; Li Q; Wang E
Oncotarget; 2017 Feb; 8(9):15689-15703. PubMed ID: 28152516
[TBL] [Abstract][Full Text] [Related]
25. High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis.
Chen R; Zhu S; Fan XG; Wang H; Lotze MT; Zeh HJ; Billiar TR; Kang R; Tang D
Hepatology; 2018 May; 67(5):1823-1841. PubMed ID: 29149457
[TBL] [Abstract][Full Text] [Related]
26. COX-2 Forms Regulatory Loop with YAP to Promote Proliferation and Tumorigenesis of Hepatocellular Carcinoma Cells.
Xu G; Wang Y; Li W; Cao Y; Xu J; Hu Z; Hao Y; Hu L; Sun Y
Neoplasia; 2018 Apr; 20(4):324-334. PubMed ID: 29505957
[TBL] [Abstract][Full Text] [Related]
27. RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma.
Ahn EY; Kim JS; Kim GJ; Park YN
Mol Cancer Res; 2013 Jul; 11(7):748-58. PubMed ID: 23594797
[TBL] [Abstract][Full Text] [Related]
28. Yes-associated protein/TEA domain family member and hepatocyte nuclear factor 4-alpha (HNF4α) repress reciprocally to regulate hepatocarcinogenesis in rats and mice.
Cai WY; Lin LY; Hao H; Zhang SM; Ma F; Hong XX; Zhang H; Liu QF; Ye GD; Sun GB; Liu YJ; Li SN; Xie YY; Cai JC; Li BA
Hepatology; 2017 Apr; 65(4):1206-1221. PubMed ID: 27809333
[TBL] [Abstract][Full Text] [Related]
29. Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway.
Dong L; Lin F; Wu W; Liu Y; Huang W
Int J Med Sci; 2018; 15(6):645-652. PubMed ID: 29725256
[TBL] [Abstract][Full Text] [Related]
30. [YAP induces chromosomal instability in liver cancer patients].
Weiler S
Pathologe; 2018 Dec; 39(Suppl 2):185-188. PubMed ID: 30206654
[TBL] [Abstract][Full Text] [Related]
31. S1P Stimulates Proliferation by Upregulating CTGF Expression through S1PR2-Mediated YAP Activation.
Cheng JC; Wang EY; Yi Y; Thakur A; Tsai SH; Hoodless PA
Mol Cancer Res; 2018 Oct; 16(10):1543-1555. PubMed ID: 29903770
[TBL] [Abstract][Full Text] [Related]
32. Bile acids activate YAP to promote liver carcinogenesis.
Anakk S; Bhosale M; Schmidt VA; Johnson RL; Finegold MJ; Moore DD
Cell Rep; 2013 Nov; 5(4):1060-9. PubMed ID: 24268772
[TBL] [Abstract][Full Text] [Related]
33. The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis.
Zhang X; Qiao Y; Wu Q; Chen Y; Zou S; Liu X; Zhu G; Zhao Y; Chen Y; Yu Y; Pan Q; Wang J; Sun F
Nat Commun; 2017 May; 8():15280. PubMed ID: 28474680
[TBL] [Abstract][Full Text] [Related]
34. Scaffolding Protein IQGAP1 Is Dispensable, but Its Overexpression Promotes Hepatocellular Carcinoma via YAP1 Signaling.
Delgado ER; Erickson HL; Tao J; Monga SP; Duncan AW; Anakk S
Mol Cell Biol; 2021 Mar; 41(4):. PubMed ID: 33526450
[TBL] [Abstract][Full Text] [Related]
35. Role of the transcriptional coactivators YAP/TAZ in liver cancer.
Zhang S; Zhou D
Curr Opin Cell Biol; 2019 Dec; 61():64-71. PubMed ID: 31387016
[TBL] [Abstract][Full Text] [Related]
36. Targeting YAP and Hippo signaling pathway in liver cancer.
Liu AM; Xu MZ; Chen J; Poon RT; Luk JM
Expert Opin Ther Targets; 2010 Aug; 14(8):855-68. PubMed ID: 20545481
[TBL] [Abstract][Full Text] [Related]
37. Effect of Mst1 overexpression on the growth of human hepatocellular carcinoma HepG2 cells and the sensitivity to cisplatin in vitro.
Xu C; Liu C; Huang W; Tu S; Wan F
Acta Biochim Biophys Sin (Shanghai); 2013 Apr; 45(4):268-79. PubMed ID: 23419720
[TBL] [Abstract][Full Text] [Related]
38. Integration of Hippo signalling and the unfolded protein response to restrain liver overgrowth and tumorigenesis.
Wu H; Wei L; Fan F; Ji S; Zhang S; Geng J; Hong L; Fan X; Chen Q; Tian J; Jiang M; Sun X; Jin C; Yin ZY; Liu Q; Zhang J; Qin F; Lin KH; Yu JS; Deng X; Wang HR; Zhao B; Johnson RL; Chen L; Zhou D
Nat Commun; 2015 Feb; 6():6239. PubMed ID: 25695629
[TBL] [Abstract][Full Text] [Related]
39. Myricetin Suppresses the Propagation of Hepatocellular Carcinoma via Down-Regulating Expression of YAP.
Li M; Chen J; Yu X; Xu S; Li D; Zheng Q; Yin Y
Cells; 2019 Apr; 8(4):. PubMed ID: 30999669
[TBL] [Abstract][Full Text] [Related]
40. Deubiquitinase YOD1: the potent activator of YAP in hepatomegaly and liver cancer.
Kim Y; Jho EH
BMB Rep; 2017 Jun; 50(6):281-282. PubMed ID: 28502290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]